Sarepta Therapeutics, Inc. business relationships
Companies named in Sarepta Therapeutics, Inc.’s 10-K filed 2026-03-02, and public companies whose annual reports name Sarepta Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 6% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Sarepta Therapeutics, Inc.’s annual report 10
“** See revenue section above for further details regarding product supply sold to Roche.” SEC filing
“...year ended December 31, 2025, the Company recorded and paid $ 5.1 million due to Nationwide as a result of the Japan Approval Milestone received from Roche as an in-licensed right intangible asset in its consolidated balance sheets in accordance with the Company's license agreement with Nationwide.” SEC filing
“We have received approval for sale and marketing for ELEVIDYS in the U.S., and our strategic partner Roche has received approvals in certain other countries.” SEC filing
“In addition, to the extent we rely on Roche to commercialize any products for which we obtain regulatory approval, we will receive less revenues than if we commercialized these products ourselves.” SEC filing
“The in-licensed rights primarily relate to agreements with BioMarin Pharmaceutical, Inc. ("BioMarin"), the University of Western Australia ("UWA"), the Research Institute at Nationwide Children's Hospital ("Nationwide") and Parent Project Muscular Dystrophy ("PPMD").” SEC filing
“our expectation that our partnership with Catalent, Inc. ("Catalent") will support our clinical and commercial manufacturing demand for certain of our programs, while also acting as a manufacturing platform for potential future gene therapy programs;” SEC filing
“For more information related to the leases embedded in manufacturing and supply agreements with Catalent, Inc. ("Catalent"), please refer to Note 23, Commitments and Contingencies .” SEC filing
“...anufacturing expenses primarily due to costs associated with the termination of the development, commercial manufacturing and supply agreement (the "Thermo Agreement") related to Brammer Bio MA, LLC, an affiliate of Thermo Fisher Scientific, Inc. ("Thermo") in 2024, with no similar activity in 2025;” SEC filing
“...Company entered into a clinical and commercial supply agreement in December 2018, as subsequently amended in June 2020, with Aldevron LLC ("Aldevron") for the supply of plasmid DNA to fulfill its needs for gene therapy clinical trials and commercial supply (collectively, the "Aldevron Agreements").” SEC filing
“Exclusive License and Collaboration Agreement, dated November 25, 2024, between Sarepta Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.” SEC filing
Companies whose annual reports name Sarepta Therapeutics, Inc. 4
“...raZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, SanegeneBio, Sarepta Therapeutics, Inc., Silence Therapeutics plc, Takeda Pharmaceutical Company Ltd., and Wave Life Sciences, Ltd., as well as our collaborators Regeneron, Roche, Sanofi and Vi...” SEC filing
“For example, adverse events in gene therapy clinical trials, such as the more recent deaths in trials conducted by both Sarepta Therapeutics, Inc. and Capsida Biotherapeutics, Inc., respectively, and the occurrence of a brain tumor after an experimental gene therapy by REGENXBio Inc., may adversely...” SEC filing
“...evaluating a sigma-1 receptor agonist, (v) PTC Therapeutics evaluating a splicing modifier (licensed to Novartis), (vi) Sarepta Therapeutics evaluating an siRNA, (vii) Skyhawk Therapeutics evaluating a splicing modifier, (viii) uniQure evaluating an AAV-delivered miRNA, (ix) Vaccinex evaluating a mo...” SEC filing
“Evaluation of distinct performance obligations related to the license and collaboration agreement with Sarepta Therapeutics, Inc” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.